Skip to main content
. Author manuscript; available in PMC: 2014 Jul 1.
Published in final edited form as: Int J Cancer. 2013 Feb 8;133(1):21–30. doi: 10.1002/ijc.27994

Figure 5. Effect of AKT inhibition and GRP78 knockdown on cisplatin mediated cytotoxicity.

Figure 5

A, Western analysis examining the dose response MK2206 on AKT and GRP78 in Ishikawa cells. B EC50 assays examining the cytotoxic effects of cisplatin on Ishikawa as described in materials and methods. Treatment groups were parental control (Cisplatin), or cisplatin with siRNA control (Cisplatin+siCon), or cisplatin+GRP78 knockdown (Cisplatin +siGRP78) with or without combination with MK2206 (5nM, 50nM). Graph is representative of one of five independent experiments. C, Western analysis examining the dose response MK2206 on AKT and GRP78 in AN3CA cells. B EC50 assays examining the cytotoxic effects of cisplatin on AN3CA as described in materials and methods. Treatment groups were parental control (Cisplatin), or cisplatin with siRNA control (Cisplatin+siCon), or cisplatin+GRP78 knockdown (Cisplatin +siGRP78) with or without combination with MK2206 (5nM, 50nM). Graph is representative of one of five independent experiments.